AU2021268223C1 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof - Google Patents
Compound having KDM5 inhibitory activity and pharmaceutical use thereofInfo
- Publication number
- AU2021268223C1 AU2021268223C1 AU2021268223A AU2021268223A AU2021268223C1 AU 2021268223 C1 AU2021268223 C1 AU 2021268223C1 AU 2021268223 A AU2021268223 A AU 2021268223A AU 2021268223 A AU2021268223 A AU 2021268223A AU 2021268223 C1 AU2021268223 C1 AU 2021268223C1
- Authority
- AU
- Australia
- Prior art keywords
- general formula
- alkyl
- compound
- azabicyclo
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/088925 | 2020-05-07 | ||
| CN2020088925 | 2020-05-07 | ||
| PCT/CN2021/091843 WO2021223699A1 (en) | 2020-05-07 | 2021-05-06 | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2021268223A1 AU2021268223A1 (en) | 2022-12-08 |
| AU2021268223B2 AU2021268223B2 (en) | 2025-10-09 |
| AU2021268223C1 true AU2021268223C1 (en) | 2026-07-09 |
Family
ID=76159223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021268223A Active AU2021268223C1 (en) | 2020-05-07 | 2021-05-06 | Compound having KDM5 inhibitory activity and pharmaceutical use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11691968B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4471027A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7643466B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102937044B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115461338B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021268223C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022005A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181604A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3037418T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297900B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013692A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI895412B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021223699A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999183A4 (en) * | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| AU2021268223C1 (en) | 2020-05-07 | 2026-07-09 | Ono Pharmaceutical Co., Ltd. | Compound having KDM5 inhibitory activity and pharmaceutical use thereof |
| JP2023070165A (ja) * | 2021-11-05 | 2023-05-18 | 小野薬品工業株式会社 | アザビシクロ環化合物の結晶 |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Kdm5阻害作用を有する化合物を含有する医薬組成物 |
| TW202612686A (zh) * | 2024-05-17 | 2026-04-01 | 日商小野藥品工業股份有限公司 | 失智症之行動及心理症狀之預防、進展抑制及/或治療劑 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057924A1 (en) * | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB0311859D0 (en) | 2003-05-22 | 2003-06-25 | Merck Sharp & Dohme | Therapeutic agents |
| EP1765379A4 (en) | 2004-06-17 | 2009-05-27 | Transform Pharmaceuticals Inc | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| WO2009047161A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| CN108341819B (zh) | 2017-01-22 | 2021-06-15 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂及其用途 |
| EP3999183A4 (en) | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| AU2021268223C1 (en) | 2020-05-07 | 2026-07-09 | Ono Pharmaceutical Co., Ltd. | Compound having KDM5 inhibitory activity and pharmaceutical use thereof |
-
2021
- 2021-05-06 AU AU2021268223A patent/AU2021268223C1/en active Active
- 2021-05-06 CN CN202180032139.2A patent/CN115461338B/zh active Active
- 2021-05-06 IL IL297900A patent/IL297900B2/en unknown
- 2021-05-06 BR BR112022022005A patent/BR112022022005A2/pt unknown
- 2021-05-06 EP EP24182835.9A patent/EP4471027A1/en active Pending
- 2021-05-06 ES ES21728166T patent/ES3037418T3/es active Active
- 2021-05-06 KR KR1020227037880A patent/KR102937044B1/ko active Active
- 2021-05-06 EP EP21728166.6A patent/EP4146645B1/en active Active
- 2021-05-06 TW TW110116409A patent/TWI895412B/zh active
- 2021-05-06 JP JP2022567355A patent/JP7643466B2/ja active Active
- 2021-05-06 KR KR1020267006670A patent/KR20260046494A/ko active Pending
- 2021-05-06 CA CA3181604A patent/CA3181604A1/en active Pending
- 2021-05-06 WO PCT/CN2021/091843 patent/WO2021223699A1/en not_active Ceased
- 2021-05-06 MX MX2022013692A patent/MX2022013692A/es unknown
-
2022
- 2022-10-24 US US17/971,844 patent/US11691968B2/en active Active
-
2023
- 2023-05-05 US US18/144,030 patent/US12269817B2/en active Active
-
2024
- 2024-10-02 JP JP2024173464A patent/JP7643632B2/ja active Active
-
2025
- 2025-02-26 JP JP2025029239A patent/JP2025081677A/ja not_active Withdrawn
- 2025-02-28 US US19/067,084 patent/US20250214984A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057924A1 (en) * | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022022005A2 (pt) | 2022-12-13 |
| CN115461338B (zh) | 2024-02-20 |
| US12269817B2 (en) | 2025-04-08 |
| JP7643466B2 (ja) | 2025-03-11 |
| US20230109293A1 (en) | 2023-04-06 |
| US20250214984A1 (en) | 2025-07-03 |
| CN115461338A (zh) | 2022-12-09 |
| JP7643632B2 (ja) | 2025-03-11 |
| MX2022013692A (es) | 2022-11-30 |
| KR20260046494A (ko) | 2026-04-07 |
| JP2025081677A (ja) | 2025-05-27 |
| EP4471027A1 (en) | 2024-12-04 |
| JP2024177345A (ja) | 2024-12-19 |
| KR20230007352A (ko) | 2023-01-12 |
| EP4146645B1 (en) | 2025-06-25 |
| IL297900B2 (en) | 2026-04-01 |
| US20230271952A1 (en) | 2023-08-31 |
| EP4146645A1 (en) | 2023-03-15 |
| ES3037418T3 (en) | 2025-10-01 |
| KR102937044B1 (ko) | 2026-03-09 |
| IL297900A (en) | 2023-01-01 |
| NZ793960A (en) | 2025-12-19 |
| JP2023524547A (ja) | 2023-06-12 |
| AU2021268223B2 (en) | 2025-10-09 |
| WO2021223699A1 (en) | 2021-11-11 |
| CA3181604A1 (en) | 2021-11-11 |
| TW202200571A (zh) | 2022-01-01 |
| AU2021268223A1 (en) | 2022-12-08 |
| US11691968B2 (en) | 2023-07-04 |
| IL297900B1 (en) | 2025-12-01 |
| TWI895412B (zh) | 2025-09-01 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2026 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2026 |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2026 |